Tags

Type your tag names separated by a space and hit enter

High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis.
Med Mycol. 2020 Feb 01; 58(2):197-200.MM

Abstract

Malassezia pachydermatis, a lipophilic and aerobic yeast, is a causative agent of Malassezia dermatitis, a common skin mycosis in dogs and cats. This fungus is also responsible for zoonotic fungal infections in human neonates. Ravuconazole (RVZ) is an antifungal azole compound and the active metabolite of fosravuconazole, which was approved for use in humans in Japan in 2018. In the present study, in vitro RVZ susceptibility and multi-azole resistance of 13 clinical M. pachydermatis strains was investigated using the modified Clinical and Laboratory Standards Institute M27-A3 test. The minimum inhibitory concentrations (MICs) for the 13 isolates ranged from 0.094 to >32 mg/L for itraconazole (ITZ) and from 0.5 to >32 mg/l for RVZ. Similarly, MICs for ITZ- or RVZ-resistant strains (MICs >32 mg/l) were also >32 mg/l for clotrimazole (CTZ), >32 mg/l for miconazole (MCZ), and 0.25 to >32 mg/L for voriconazole (VRZ). BLAST analysis using the NCBI database showed that ERG11 cDNA of the RVZ-resistant strain encoded Gly at codon 461 and Asp in cytochrome p450 encoded by M. pachydermatis ERG11 mRNA. This work is the first report to describe that an RVZ-resistant M. pachydermatis strain contains ERG11 mutations. The affinity of the protein encoded by ERG11 for RVZ may differ from that of ITZ. Therefore, RVZ has considerable therapeutic potential for treating ITZ-resistant canine Malassezia dermatitis. However, RVZ-resistant strains already exist in canine Malassezia dermatitis in Japan.

Authors+Show Affiliations

Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, 1866 Kameino, Fujisawa, Kanagawa 252-0880, Japan.Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, 1866 Kameino, Fujisawa, Kanagawa 252-0880, Japan.Dermatology Services for Dogs and Cats, 1F TANDEM-HIRANO Bldg. 2-11-14 Hirano, Koto-ku, Tokyo 135-0023, Japan.Dermatology Services for Dogs and Cats, 1F TANDEM-HIRANO Bldg. 2-11-14 Hirano, Koto-ku, Tokyo 135-0023, Japan.Nagano Hongo Animal Clinic, 9-7-9 Miwa, Nagano-City, Nagano 380-0803, Japan.Sennan Animal Hospital, 3-2297-1 Noda, Kumatori, Sennan, Osaka 590-0451, Japan.Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, 1866 Kameino, Fujisawa, Kanagawa 252-0880, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31329927

Citation

Kano, Rui, et al. "High Multi-azole-resistant Malassezia Pachydermatis Clinical Isolates From Canine Malassezia Dermatitis." Medical Mycology, vol. 58, no. 2, 2020, pp. 197-200.
Kano R, Aramaki C, Murayama N, et al. High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis. Med Mycol. 2020;58(2):197-200.
Kano, R., Aramaki, C., Murayama, N., Mori, Y., Yamagishi, K., Yokoi, S., & Kamata, H. (2020). High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis. Medical Mycology, 58(2), 197-200. https://doi.org/10.1093/mmy/myz037
Kano R, et al. High Multi-azole-resistant Malassezia Pachydermatis Clinical Isolates From Canine Malassezia Dermatitis. Med Mycol. 2020 Feb 1;58(2):197-200. PubMed PMID: 31329927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis. AU - Kano,Rui, AU - Aramaki,Chizu, AU - Murayama,Nobuo, AU - Mori,Yuko, AU - Yamagishi,Kentaro, AU - Yokoi,Shinichi, AU - Kamata,Hiroshi, PY - 2019/02/18/received PY - 2019/03/26/revised PY - 2019/03/30/accepted PY - 2019/7/23/pubmed PY - 2020/9/15/medline PY - 2019/7/23/entrez KW - Malassezia pachydermatis KW - Antifungal susceptibility KW - azole KW - multi-azole resistance KW - ravuconazole SP - 197 EP - 200 JF - Medical mycology JO - Med. Mycol. VL - 58 IS - 2 N2 - Malassezia pachydermatis, a lipophilic and aerobic yeast, is a causative agent of Malassezia dermatitis, a common skin mycosis in dogs and cats. This fungus is also responsible for zoonotic fungal infections in human neonates. Ravuconazole (RVZ) is an antifungal azole compound and the active metabolite of fosravuconazole, which was approved for use in humans in Japan in 2018. In the present study, in vitro RVZ susceptibility and multi-azole resistance of 13 clinical M. pachydermatis strains was investigated using the modified Clinical and Laboratory Standards Institute M27-A3 test. The minimum inhibitory concentrations (MICs) for the 13 isolates ranged from 0.094 to >32 mg/L for itraconazole (ITZ) and from 0.5 to >32 mg/l for RVZ. Similarly, MICs for ITZ- or RVZ-resistant strains (MICs >32 mg/l) were also >32 mg/l for clotrimazole (CTZ), >32 mg/l for miconazole (MCZ), and 0.25 to >32 mg/L for voriconazole (VRZ). BLAST analysis using the NCBI database showed that ERG11 cDNA of the RVZ-resistant strain encoded Gly at codon 461 and Asp in cytochrome p450 encoded by M. pachydermatis ERG11 mRNA. This work is the first report to describe that an RVZ-resistant M. pachydermatis strain contains ERG11 mutations. The affinity of the protein encoded by ERG11 for RVZ may differ from that of ITZ. Therefore, RVZ has considerable therapeutic potential for treating ITZ-resistant canine Malassezia dermatitis. However, RVZ-resistant strains already exist in canine Malassezia dermatitis in Japan. SN - 1460-2709 UR - https://www.unboundmedicine.com/medline/citation/31329927/High_multi_azole_resistant_Malassezia_pachydermatis_clinical_isolates_from_canine_Malassezia_dermatitis_ L2 - https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/myz037 DB - PRIME DP - Unbound Medicine ER -